Cargando…

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours

INTRODUCTION: Somatostatin‐secreting neuroendocrine tumours may present with diabetes, cholelithiasis and steatorrhoea. In addition, hypoglycaemia has been associated with somatostatinomas. However, the mechanism of hypoglycaemia in patients with somatostatinomas has not been well characterized. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiesli, Peter, Pavlicek, Vojtech, Brändle, Michael, Pfammatter, Thomas, Perren, Aurel, Schmid, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775468/ https://www.ncbi.nlm.nih.gov/pubmed/31592116 http://dx.doi.org/10.1002/edm2.83

Ejemplares similares

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
por: Haris, Basma, et al.
Publicado: (2020)

Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression
por: Di Domenico, Annunziata, et al.
Publicado: (2020)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

Impact of Growth Hormone on Cystatin C
por: Sze, Lisa, et al.
Publicado: (2013)

ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology
por: van Velthuysen, Marie‐Louise F., et al.
Publicado: (2022)

Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours
por: Childs, Alexa, et al.
Publicado: (2016)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways
por: Cakir, Mehtap, et al.
Publicado: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2 – clinical implications
por: Cakir, Mehtap, et al.
Publicado: (2010)

Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia
por: Kristensen, Peter L, et al.
Publicado: (2016)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours
por: Mills, Logan, et al.
Publicado: (2017)

Serotonin-Secreting Neuroendocrine Tumours of the Pancreas
por: Milanetto, Anna Caterina, et al.
Publicado: (2020)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Evaluation of the synthetic somatostatin analogue SMS 201-995 in patients with hypoglycaemia associated with hepatocellular carcinoma.
por: Joffe, B. I., et al.
Publicado: (1988)

Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
por: Hall, G H, et al.
Publicado: (2002)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

Improved Personalised Neuroendocrine Tumours’ Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification
por: Stolniceanu, Cati Raluca, et al.
Publicado: (2021)

DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors
por: Simon, Tincy, et al.
Publicado: (2022)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour
por: Abell, Sally K, et al.
Publicado: (2015)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

Casting a Wider NET: Pancreatic Exocrine Insufficiency Induced by Somatostatin Analogues among Patients with Neuroendocrine Tumours?
por: Hall, Lewis A., et al.
Publicado: (2023)

Tumour-associated hypoglycaemia in a murine cachexia model.
por: McDevitt, T. M., et al.
Publicado: (1992)

Regulating Glucagon Secretion: Somatostatin in the Spotlight
por: Rutter, Guy A.
Publicado: (2009)

Update on Histological Reporting Changes in Neuroendocrine Neoplasms
por: Bräutigam, Konstantin, et al.
Publicado: (2021)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors
por: Sadowski, Samira M, et al.
Publicado: (2017)

Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life
por: Faggiano, Antongiulio, et al.
Publicado: (2015)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
por: Sorbye, Halfdan, et al.
Publicado: (2020)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors
por: Wang, Ling, et al.
Publicado: (2013)

Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer
por: Mori, Hiroshi, et al.
Publicado: (2018)

Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix
por: Saponjski, Jelena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_656mkp4akqe50fkn1vaacljrtr